NSABP B-61 lidERA
B-61 lidERA
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC-9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen-Receptor Positive , HER2 Negative Early Breast Cancer
Patient Population:
Patients with Estrogen receptor positive, Her-2 negative early breast cancer
Target Accrual: 350 patients
Status: Recruiting
ClinicialTrials.gov Identifier:
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Adjuvant GDC-9545 Compared with Physician's Choice of Adjuvant Endocrine Monotherapy in Patients with Estrogen-Receptor Positive , HER2 Negative Early Breast Cancer
Patient Population:
Patients with Estrogen receptor positive, Her-2 negative early breast cancer
Target Accrual: 350 patients
Status: Recruiting
ClinicialTrials.gov Identifier: